^
    Back
    Association details:
    Biomarker:NCAM1 positive
    Cancer:Multiple Myeloma
    Drug:lorvotuzumab mertansine (IMGN901) (Microtubule inhibitor, CD56-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    IMGN901 in Combination With Lenalidomide and Dexamethasone

    Excerpt:
    ...- Patients must have CD56-positive, relapsed or relapsed/refractory multiple myeloma....
    Trial ID:
    NCT00991562
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

    Excerpt:
    ...- CD56-positive disease confirmed by immunohistochemistry or flow cytometry...
    Trial ID:
    IMGN901
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Lymphoma Myeloma Leuk
    Title:

    A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

    Excerpt:
    Here, we present results from the phase I clinical trial to assess the safety, tolerability, and pharmacokinetics (PK) of lorvotuzumab mertansine when administered as monotherapy to patients with CD56-positive (CD56+) relapsed or RRMM….Despite a high proportion of patients with relapsed and/or refractory MM (56.8%), stable disease or better was noted in 42.9% of patients, and these patients had a long duration of response (median, 15.5 months).
    DOI:
    https://doi.org/10.1016/j.clml.2018.08.018